Related Experiment Video
Updated: Dec 14, 2025
Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
A Novel Peptide, CK2.3, Improved Bone Formation in Ovariectomized Sprague Dawley Rats
Linda Sequeira1, John Nguyen1, Liyun Wang2
1Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Abstract:
Osteoporosis is a bone disease that has no definite cure. Current treatments for osteoporosis are divided into two categories: anti-resorptive and anabolic. However, these treatments are not perfect and have considerable risks. In addition, bone quality often declines over time with these treatments. We designed a peptide, CK2.3, that has both anabolic and anti-resorptive effects on bone. We reported that CK2.3 induced osteoblastic mineralization, promoted bone formation, and suppressed osteoclastogenesis in vivo. The effect of CK2.3 to rescue an osteoporosis phenotype model has never been shown. In this study, we demonstrated the effect of CK2.3 in ovariectomized rats, a standard model of osteoporosis. We systemically injected CK2.3 at 2.3 µg/kg each day for five consecutive days. Micro-computed tomography indicated that CK2.3 increased bone mineral density, (bone volume/tissue volume) BV/TV and (trabecular number) TbN, and decreased (trabecular space) TbSp in the femoral head. Similarly, single photon absorptiometry showed that treatment with CK2.3 increased bone mineral density in the lumbar spine and the pelvis. Additionally, we observed increased femoral shaft stiffness with ovariectomized rats treated with CK2.3. We also detected no significant changes in the weight of organs such as the heart, lung, liver, kidney, and spleen. An advantage of CK2.3 over current treatments was that it not only promoted bone formation but also improved fracture resistance. In conclusion, we demonstrated CK2.3 as a new anabolic treatment for osteoporosis.
Insights
A novel peptide, CK2.3, shows promise as an osteoporosis treatment. It promotes bone formation and improves bone density and strength in ovariectomized rats, offering a potential new anabolic therapy.
Area of Science:
- Biomedical research
- Bone biology
- Pharmacology
Background:
- Osteoporosis lacks a definitive cure, and current treatments have limitations and risks.
- Existing therapies include anti-resorptive and anabolic agents, but bone quality can decline.
- There is a need for novel osteoporosis treatments with improved efficacy and safety profiles.
Purpose of the Study:
- To evaluate the efficacy of a newly designed peptide, CK2.3, in an established osteoporosis model.
- To determine if CK2.3 can rescue osteoporosis phenotypes in ovariectomized rats.
- To assess the anabolic and anti-resorptive effects of CK2.3 on bone.
Main Methods:
- Ovariectomized rats, a standard osteoporosis model, were treated with daily systemic injections of CK2.3.
- Bone mineral density, bone structure, and mechanical properties were assessed using micro-computed tomography and single photon absorptiometry.
- Organ weights were monitored to evaluate potential systemic toxicity.
Main Results:
- CK2.3 treatment significantly increased bone mineral density, bone volume/tissue volume (BV/TV), and trabecular number (TbN) in the femoral head.
- CK2.3 also increased bone mineral density in the lumbar spine and pelvis, and enhanced femoral shaft stiffness.
- No significant changes in the weight of major organs were observed, suggesting a favorable safety profile.
Conclusions:
- CK2.3 demonstrated significant anabolic effects, improving bone density, structure, and mechanical strength in an osteoporosis model.
- The peptide also exhibited anti-resorptive properties, suppressing osteoclastogenesis.
- CK2.3 represents a promising new anabolic therapeutic agent for osteoporosis, potentially offering improved fracture resistance over current treatments.
